Innovest Global, Inc. Stock Symbol IVST is aPublic diversified Holding company that is already a ten-bagger (Up 1000% in
the market) this year with much more on the way based on fundamentals AND
technical from our research. Here's what we found:Innovest Global, Inc. (OTC Markets: IVST) isfundamentally in the Conglomerates industry. IVST is a diversified holding
company with operations in commercial and industrial products and services,
energy, biotechnology, and health services. The primary growth strategy of IVST
is to acquire niche, high-growth businesses that are capable of generating
significant annual revenue and that fit with other subsidiaries in their
divisions. Planned subsidiaries operate across telehealth, biotech, building
materials, commercial energy, business-to-business distribution, national call
center and auto sales. Since January IVST has acquired 5 companies and those
subsidiaries have grown in revenue 50% post acquisition. That means that when
IVST buys a company, that company grows after the acquisition
exponentially. Based out of Cleveland, Ohio, IVST iseasily one of the better fundamental companies trading on the OTC marketplace
and in fact is Ohio’s fastest growing publicly traded company. InnovestGlobal, Inc. is already up 10-fold in 2018 after starting off in Janaround $0.02. Since then the stock hit a YTD all-time high of $0.55 in March
2018 it has since settled into a strong support around .23-.25. IVST continuesto hold onto the substantial gains thus far and from our estimates is ready for
the next leg, which we hope will be into the .50 range. Based upon the
company’s strong fundamental AND technical picture, Innovest Global,Inc. could easily retake its all-time high by the end of 2018.What a stock structure IVST hasfolks! The company has an amazing unchanged free-trading float of 11,796,710
common shares with no convertible debts, no warrantsor options outstanding, and employs 45.Onto the meat and potatoes:IVST owns 20% of StemVax Therapeutics, which happensto be the first company in its Biotech Division.StemVax Therapeutics is a Translational Biotechnology Companythat develops novel therapies for brain tumor patients. We focus our efforts on
developing immunotherapeutic approaches to treating patients with Glioblastoma
Multiforme (GBM), a devastating brain cancer. We also focus our research
efforts on novel drug development to target Cancer Stem cells and other
multi-resistant cancer cells. Lead by world-renowned neuroscientist, Dr. Dwain
Morris-Irvin, the Biotech & Health Sciences Division is currently focused
on commercializing StemVax’s cancer vaccination therapytechnology. The cancer vaccination therapy technology was just recently awarded
a U.S. patent! We seek to make a difference in patient’s lives bringing new
beginnings to the market by developing novel therapeutics.IVST’s management team has been extremely busy with its pendingmega-acquisition of a building materials company, which produces $30million in annual revenues! Once the building materials company isacquired, it will serve as Innovest Global’s third division.The initial discussions began back in March 2018, followed by formal
negotiations in April 2018. In June, Innovest managementformally proposed the acquisition pitch to the target company’s board of
directors. Upon conclusion of the presentation, both parties had signed and
executed a Letter of Intent (LOI) document. In late August 2018, it was
announced that both parties have effectively reached an agreement on the
acquisition transaction structure and long form documents. We expect this to
“formally” close at any moment.IVST has the vision and model of Berkshire-Hathaway; we lookforward to its evolution!
